Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

Who could benefit from this research

What this research studies

Researchers will examine genetic and epigenetic factors in primary triple-negative breast cancer tumors from patients of African ancestry, linking these differences to immune styles and tumor biology. The project will combine genomic data with clinical information to map how ancestry influences tumor behavior. By analyzing multiple data types, the study aims to identify patterns that could explain disparities in treatment response and outcomes. Results could guide more personalized approaches for TNBC in African-descended patients.

Why it matters

Where this research is happening

• Tuskegee University
  Tuskegee Institute, United States Active

Researchers

• Principal investigator: Bedi, Deepa — Tuskegee University
• Study coordinator: Bedi, Deepa

Related research

Other NIH-funded projects on the same topics.

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

• Rac-enhanced CAR-Macrophages against TNBC

  A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

  NIH research University of Louisville · Louisville, United States · NIH-11520503

• A new peptide therapy to help treat metastatic triple-negative breast cancer

  A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11453153

• Photoacoustic imaging to tailor antibody-drug therapy for TNBC

  A non-invasive imaging approach using light-based sound waves (photoacoustic imaging) is being developed to guide and personalize antibody-drug conjugate therapy for women with triple-negative breast cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11445261

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.